Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Intangibles (2022 - 2025)

Neurocrine Biosciences filings provide 4 years of Intangibles readings, the most recent being $35.7 million for Q3 2025.

  • On a quarterly basis, Intangibles rose 3.48% to $35.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.7 million, a 3.48% increase, with the full-year FY2024 number at $36.5 million, up 2.82% from a year prior.
  • Intangibles hit $35.7 million in Q3 2025 for Neurocrine Biosciences, down from $37.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $37.2 million in Q4 2022 to a low of $33.5 million in Q2 2024.
  • Median Intangibles over the past 4 years was $36.0 million (2025), compared with a mean of $35.8 million.
  • Biggest five-year swings in Intangibles: fell 9.21% in 2024 and later rose 11.04% in 2025.
  • Neurocrine Biosciences' Intangibles stood at $37.2 million in 2022, then fell by 4.57% to $35.5 million in 2023, then rose by 2.82% to $36.5 million in 2024, then fell by 2.19% to $35.7 million in 2025.
  • The last three reported values for Intangibles were $35.7 million (Q3 2025), $37.2 million (Q2 2025), and $36.4 million (Q1 2025) per Business Quant data.